KR100463369B1 - 피페리딘-4-설폰아미드 화합물, 이들의 제조 방법 및 이들을 함유하는 약제학적 조성물 - Google Patents

피페리딘-4-설폰아미드 화합물, 이들의 제조 방법 및 이들을 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR100463369B1
KR100463369B1 KR10-2001-0004591A KR20010004591A KR100463369B1 KR 100463369 B1 KR100463369 B1 KR 100463369B1 KR 20010004591 A KR20010004591 A KR 20010004591A KR 100463369 B1 KR100463369 B1 KR 100463369B1
Authority
KR
South Korea
Prior art keywords
group
compound
branched
linear
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-2001-0004591A
Other languages
English (en)
Korean (ko)
Other versions
KR20010078210A (ko
Inventor
쟝-루이 페글리옹
아이메 데셍지
크리스토프 뿌아떼벵
쟝-뽈 빌라인느
니꼴 빌레누브
까떼린느 톨롱
마리-삐에르 부르귀농
Original Assignee
르 라보레또레 쎄르비에르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 르 라보레또레 쎄르비에르 filed Critical 르 라보레또레 쎄르비에르
Publication of KR20010078210A publication Critical patent/KR20010078210A/ko
Application granted granted Critical
Publication of KR100463369B1 publication Critical patent/KR100463369B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
KR10-2001-0004591A 2000-01-31 2001-01-31 피페리딘-4-설폰아미드 화합물, 이들의 제조 방법 및 이들을 함유하는 약제학적 조성물 Expired - Fee Related KR100463369B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00.01171 2000-01-31
FR0001171A FR2804429B1 (fr) 2000-01-31 2000-01-31 Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
KR20010078210A KR20010078210A (ko) 2001-08-20
KR100463369B1 true KR100463369B1 (ko) 2004-12-23

Family

ID=8846469

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2001-0004591A Expired - Fee Related KR100463369B1 (ko) 2000-01-31 2001-01-31 피페리딘-4-설폰아미드 화합물, 이들의 제조 방법 및 이들을 함유하는 약제학적 조성물

Country Status (24)

Country Link
US (1) US6323217B2 (enExample)
EP (1) EP1122254B1 (enExample)
JP (1) JP3513493B2 (enExample)
KR (1) KR100463369B1 (enExample)
CN (1) CN1298705C (enExample)
AR (1) AR027335A1 (enExample)
AT (1) ATE294175T1 (enExample)
AU (1) AU774808B2 (enExample)
BR (1) BR0100234A (enExample)
CA (1) CA2332513C (enExample)
DE (1) DE60110278T2 (enExample)
DK (1) DK1122254T3 (enExample)
EA (1) EA003096B1 (enExample)
ES (1) ES2241757T3 (enExample)
FR (1) FR2804429B1 (enExample)
HK (1) HK1039117B (enExample)
HU (1) HUP0100489A3 (enExample)
MX (1) MXPA01000945A (enExample)
NO (1) NO320387B1 (enExample)
NZ (1) NZ509636A (enExample)
PL (1) PL345528A1 (enExample)
PT (1) PT1122254E (enExample)
SI (1) SI1122254T1 (enExample)
ZA (1) ZA200100864B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521978A (en) * 2000-04-28 2004-10-29 Acadia Pharm Inc Compounds that affect cholinergic receptors and are particularly muscarinic agonists
EP1535912A1 (en) * 2000-04-28 2005-06-01 Arcadia Pharmaceuticals Inc. Muscarinic agonists
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AU2003284402A1 (en) * 2002-11-15 2004-06-15 Yamanouchi Pharmaceutical Co., Ltd. Antagonist to melanin-concentrating hormone receptor
JP2008507492A (ja) * 2004-07-23 2008-03-13 バイエル・クロツプサイエンス・エス・アー 殺菌剤としてのｎ−［２−（４−ピリジニル）エチル］ベンズアミド誘導体
ATE527258T1 (de) * 2004-07-28 2011-10-15 Takeda Pharmaceutical Pyrroloä2,3-cüpyridinverbindung, verfahren zu deren herstellung und anwendung
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
ES2362617T3 (es) * 2005-02-25 2011-07-08 Kowa Company, Ltd. Proceso para la producción de haluro de 4-fluoroisoquinolin-5-sulfonilo o una de sus sales.
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
CL2007003223A1 (es) * 2006-11-10 2008-01-11 Wyeth Corp Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades.
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
PL395470A1 (pl) 2011-06-29 2013-01-07 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857301A (en) * 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
US5158964A (en) * 1987-02-07 1992-10-27 Pfizer Inc. Benzoxazole sulfonamide anti-arrhythmic agents
EP0526342A1 (fr) * 1991-07-31 1993-02-03 Adir Et Compagnie Isoquinolein-5-yl sulfonamides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JPH07258217A (ja) * 1994-02-25 1995-10-09 Adir 新規な置換スルホンアミド、その製造方法及びそれらを含む薬剤組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
AU6971794A (en) * 1993-05-26 1994-12-20 Smithkline Beecham Laboratoires Pharmaceutiques Novel compounds
HN1997000027A (es) * 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158964A (en) * 1987-02-07 1992-10-27 Pfizer Inc. Benzoxazole sulfonamide anti-arrhythmic agents
US4857301A (en) * 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
EP0526342A1 (fr) * 1991-07-31 1993-02-03 Adir Et Compagnie Isoquinolein-5-yl sulfonamides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
JPH07258217A (ja) * 1994-02-25 1995-10-09 Adir 新規な置換スルホンアミド、その製造方法及びそれらを含む薬剤組成物

Also Published As

Publication number Publication date
EA200100090A2 (ru) 2001-08-27
EP1122254B1 (fr) 2005-04-27
AU774808B2 (en) 2004-07-08
PL345528A1 (en) 2001-08-13
NO20010522D0 (no) 2001-01-30
KR20010078210A (ko) 2001-08-20
DE60110278T2 (de) 2006-02-16
JP2001233874A (ja) 2001-08-28
ZA200100864B (en) 2001-08-08
JP3513493B2 (ja) 2004-03-31
NZ509636A (en) 2001-09-28
DE60110278D1 (de) 2005-06-02
FR2804429B1 (fr) 2003-05-09
HK1039117B (zh) 2007-09-07
EP1122254A3 (fr) 2001-11-28
HU0100489D0 (en) 2001-04-28
US20010034352A1 (en) 2001-10-25
PT1122254E (pt) 2005-07-29
CN1298705C (zh) 2007-02-07
SI1122254T1 (enExample) 2005-08-31
AU1674701A (en) 2001-08-02
CA2332513A1 (fr) 2001-07-31
BR0100234A (pt) 2001-08-28
MXPA01000945A (es) 2002-06-04
EA003096B1 (ru) 2002-12-26
HK1039117A1 (en) 2002-04-12
US6323217B2 (en) 2001-11-27
NO320387B1 (no) 2005-11-28
ES2241757T3 (es) 2005-11-01
NO20010522L (no) 2001-08-01
HUP0100489A2 (hu) 2002-05-29
FR2804429A1 (fr) 2001-08-03
EA200100090A3 (ru) 2001-10-22
DK1122254T3 (da) 2005-08-29
AR027335A1 (es) 2003-03-26
CN1314345A (zh) 2001-09-26
HUP0100489A3 (en) 2002-10-28
ATE294175T1 (de) 2005-05-15
CA2332513C (fr) 2005-11-29
EP1122254A2 (fr) 2001-08-08

Similar Documents

Publication Publication Date Title
KR100463369B1 (ko) 피페리딘-4-설폰아미드 화합물, 이들의 제조 방법 및 이들을 함유하는 약제학적 조성물
RU2132848C1 (ru) Производные пиперидина и пиперазина, способ их получения, содержащие их фармацевтические композиции и способ их получения
US6635657B1 (en) Aromatic amides
AU2011283684B2 (en) AMPK-activating heterocyclic compounds and methods for using the same
US8895578B2 (en) Carboxamide, sulfonamide and amine compounds and methods for using the same
CA2722139C (en) Carboxamide compounds for the treatment of metabolic disorders
US6166041A (en) 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
JPWO2004009555A1 (ja) ５−置換イソキノリン誘導体
EP1720864B1 (en) Benzimidazol substituted thiophene derivatives with activity on ikk3
MXPA05000336A (es) Antagonistas del receptor 1 de hormona de concentracion de melanina (mchir).
SK16972002A3 (sk) Beta-karbolínové deriváty použiteľné ako inhibítory fosfodiesterázy
JPH0687856A (ja) ８‐クロロ‐１１‐〔１‐〔（５‐メチル‐３‐ピリジル）メチル〕‐４‐ピペリジリデン〕‐６，１１‐ジヒドロ‐５Ｈ‐ベンゾ〔５，６〕シクロヘプタ〔１，２‐ｂ〕ピリジン
CA2031645A1 (en) Class iii antiarrhytmic agents
WO2013116491A1 (en) Carboxamide, sulfonamide and amine compounds and methods for using them
JPWO2006057270A1 (ja) 含窒素３環化合物
AU640208B2 (en) Pyridine and related aza heterocycle derivatives as cardiovascular agents
ES2224408T3 (es) Compuestos de benzopiridocicloheptano utiles para la inhibicion de la farnesil-proteina-transferasa.
US5120749A (en) Platelet activating antagonists
JP3566685B2 (ja) 新規シクロブテンジオン化合物、それらの製造法、およびそれらを含有する医薬組成物
JP4705575B2 (ja) ｉＮＯＳ阻害剤としてのクマリン類
JP3396671B2 (ja) 新規な線状又は環状尿素、その製造法、及びそれを含有する医薬組成物
EP1021448B1 (en) TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
BRPI0609147A2 (pt) 1,3-tiazol-5-carboxamidas úteis como agentes quimioterapêuticos de cáncer
AU2004202768B2 (en) New linear or cyclic ureas, a process for their preparation and pharmaceutical compositions containing them
TW202115023A (zh) 新型細胞凋亡訊號調節激酶1抑制劑

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20071012

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20081216

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20081216